Breakthrough invention in the deadliest cancer type: It wiped out all traces of tumors!

Breakthrough invention in the deadliest cancer type: It wiped out all traces of tumors!

20.11.2026 23:40

A groundbreaking development has occurred in the treatment of pancreatic cancer, known as one of the world's deadliest cancer types. A new daily pill administered alongside chemotherapy managed to stop tumor growth in 90 percent of patients in early-stage clinical trials, while in some patients it made cancer cells completely invisible on scans.

A promising development has occurred in the treatment of pancreatic cancer, one of the deadliest cancer types in the world. According to BBC News, in an early-stage clinical trial in which a daily pill called daraxonrasib was used together with chemotherapy, tumor growth stopped in the majority of patients. In some patients, the tumors became completely undetectable on imaging.

TUMOR GROWTH STOPPED IN 90% OF TUMORS

According to the report, the drug daraxonrasib was tested on 61 patients with advanced pancreatic cancer that had spread to other parts of the body.

Remarkable results were obtained in the Phase 1/2 study in which the drug was administered together with chemotherapy. While tumor growth stopped in 90% of patients, tumors shrank or disappeared in slightly more than 60%.

One of the most striking results of the study was that in approximately 8% of patients, meaning one in every 12 people, the cancer could no longer be detected on computed tomography (CT) scans.

EXPERTS FOUND THE DEVELOPMENT EXCITING

The UK-based organization Cancer Research UK evaluated the results as one of the most important advances in pancreatic cancer treatment in recent years.

Dr. Sam Godfrey, one of the organization's officials, said in a statement to the BBC that the results were extremely exciting and that the new drug could intervene in cancer mechanisms that had previously seemed very difficult to target.

Dr. Wungki Park of Memorial Sloan Kettering Cancer Center, who took part in the study, also said that the responses to the treatment were promising in terms of both rate and depth. Park stated that extending the period during which the disease is kept under control could also have a positive effect on survival time in the future.

HOW DOES THE DRUG WORK?

Daraxonrasib is a drug that targets proteins called RAS, which trigger the growth of cancer cells. It aims to prevent uncontrolled cell proliferation caused especially by KRAS mutations seen in the majority of pancreatic cancers.

Researchers assess that this mechanism may be important not only for pancreatic cancer but also for different cancer types such as lung and ovarian cancer, in which similar genetic mutations are seen.

IMPORTANT WARNING FROM EXPERTS: NOT YET A DEFINITIVE TREATMENT

Although the results are promising, experts warn that it cannot yet be said that the drug completely cures pancreatic cancer.

The patients in the study were followed for an average of 18 months. In some patients, the cancer did not reappear during this period. However, the disappearance of tumors on imaging does not mean that the disease has completely disappeared.

Experts emphasize that longer-term studies are needed to determine how long the drug's effect will last and whether the disease can be controlled in the long term.

In order to provide you with a better service, we position cookies on our site. Your personal data is collected and processed within the scope of KVKK and GDPR. For detailed information, you can review our Data Policy / Disclosure Text. By using our site, you agree to our use of cookies.', '